What You Should Know:
– Mission Bio, a pioneer in single-cell multiomic solutions for precision medicine, announced today the appointment of Brian Kim as its new Chief Executive Officer.
– Kim brings over two decades of life sciences expertise and a proven track record of driving growth and innovation to the company, poised to propel Mission Bio’s technology into clinical applications.
Brian Kim Bio/Background
Kim’s career boasts a series of successes in the life sciences sphere, showcasing his ability to navigate complex markets and build high-growth companies:
- Fortis Life Sciences: Founded and led the company to become a leading provider of proprietary reagents for clinical customers.
- LGC Biosearch Technologies: Spearheaded the division’s expansion into diagnostics and therapeutics, culminating in a successful sale in 2020.
- PerkinElmer’s Life Science and Tools: Revitalized product innovation, revamped the commercial organization, and reignited business growth.
Stuart Essig, PhD, Chairman of the Board at Mission Bio, highlights Kim’s impeccable alignment with the company’s vision: “Brian’s experience in life sciences tools commercialization and clinical end markets perfectly aligns with our mission to advance single-cell multiomics into translational research and clinical applications. He joins us at a pivotal moment when our Tapestri platform is demonstrating tangible progress in improving patient health outcomes.”
A New Chapter for Single-Cell Multiomics:
With Brian Kim at the helm, Mission Bio is poised to capitalize on the growing potential of single-cell multiomics. His leadership and expertise will be instrumental in translating this innovative technology from the lab to the clinic, paving the way for a future of personalized medicine that benefits patients worldwide.
